19.11.2015 • NewsDede WillamsMonsantoSyngenta

Monsanto Confirms it’s Still on the Prowl

After dropping its latest offer for Syngenta, worth upwards of $6 billion, three months ago Monsanto may be planning a fresh attempt to buy its Swiss rival or have another target in its crosshairs, CEO Brett Begemann has suggested. Speaking to journalists ahead of an investor day at the US group’s St Louis, Missouri, headquarters, Begemann told journalists the agribusiness giant is looking at several objects.

“We’re discussing every possible possibility, just like every other company is discussing,” the CEO said, repeated a phrase leveraged by almost every other company seeking to be non-committal. Begemann’s remarks came days after Syngenta rejected another takeover attempt – this time deflecting a $42 billion hostile bid by ChemChina. The rejection of the more lucrative Monsanto offer –the rival’s fourth altogether – and a sluggish business performance led to the resignation of Syngenta CEO Mike Mack in October, fueling rumors that the Swiss player might still be in the US group’s sights.

In the meantime, the agrochemicals and seeds markets are swimming with speculation over other possible cross-industry deals, with all of the giants – from Dow Chemical and DuPont of the US and Germany’s Bayer and BASF – thought to have cards in the game. Leveraging the same non-committal language as the Monsanto chief, Syngenta chairman Michel Demaré, told the UK business daily Financial Times in an interview that “everyone is talking to everyone else.” This, he said, is the consequence of Monsanto’s grab for his company, which has shaken the entire industry and made made other deals likely.

Opting to sidestep the spotlight, Bayer told the news agency Reuters its CropScience arm is an integral part of the group, which was newly reorganized after carving out and floating shares in its former engineering plastics business now trading as Covestro.

Virtual Event

Downstream Purification
Bioprocess Forum

Downstream Purification

Save the Date: November 21+25, 2025
Join leading scientists, process engineers, and biomanufacturing innovators for a two-day virtual event exploring the latest breakthroughs in downstream purification.

Free Expert Insights

Dual‑Targeting Breakthroughs
Advancements in Bispecific Antibody Development

Dual‑Targeting Breakthroughs

Unlock the latest breakthroughs in bispecific antibody development! Download Wiley’s free Expert Insights eBook to explore cutting-edge dual-targeting strategies, advanced purification methods, and bioanalytical technologies transforming immunotherapy and cancer treatment.

most read

Photo
28.07.2025 • NewsChemistry

VCI Welcomes US-EU Customs Deal

The German Chemical Industry Association (VCI) welcomes the fact that Ursula von der Leyen, President of the European Commission, and US President Donald Trump have averted the danger of a trade war for the time being.